BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide fragment derived from a sequence isolated in human gastric juice. Over thirty years of preclinical literature has positioned it as one of the most-studied “system-protective” peptides in animal models. This review maps the mechanistic threads that recur across the research and what remains contested.
Origin and sequence
BPC-157 is composed of fifteen amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a synthetic stable fragment of body protection compound, with no naturally occurring full-length precursor — the stable peptide is what is studied, not a natural endogenous molecule.
Angiogenesis and endothelial response
Multiple rodent studies report increased capillary formation and VEGFR2 upregulation following BPC-157 administration in injury models (Sikiric et al., 2010, 2018). The angiogenic response correlates with faster perfusion recovery in damaged tissue — a likely upstream driver of the wound-closure phenotype repeatedly observed.
Nitric oxide pathway modulation
BPC-157 appears to modulate the nitric oxide (NO) system in both directions depending on baseline state. Under NO-deficient conditions (L-NAME treatment), it restores function. Under NO-excess conditions (L-arginine loading), it dampens overshoot. This bidirectional modulation pattern is repeatedly cited but lacks a fully resolved receptor target.
Tendon, ligament, muscle models
Achilles tendon transection rodent studies show accelerated tendon outgrowth and collagen organisation with BPC-157 administered systemically or locally. Detached quadriceps muscle and crushed muscle injury models show similar acceleration of structural recovery. Mechanistic candidates include early FAK-paxillin signalling and growth-hormone receptor expression on tenocytes (Chang et al., 2014).
Gastrointestinal mucosa
The original therapeutic angle and still the most-replicated. BPC-157 protects gastric mucosa against NSAID, alcohol, and stress-induced ulceration in rodents, with corresponding histological evidence of intact mucosa and reduced inflammatory infiltrate.
Stability and reconstitution notes
BPC-157 is relatively heat-stable in lyophilised form and reconstitutes readily in bacteriostatic water. Researchers report consistent results from reconstituted material stored refrigerated for 4–6 weeks. See our solvent comparison for protocol detail.
Open questions
- No confirmed primary receptor — most signalling models are downstream-inferred
- Limited human pharmacokinetic data published
- Oral bioavailability claims rest on rodent gut models, not validated in larger species
- Long-term safety profile not characterised in published human research
BPC-157 remains one of the most-cited peptides in tissue-repair literature and a routine inclusion in research catalogues for that reason. Chempeptides supplies HPLC-verified BPC-157 with batch-specific CoA — see the research catalogue for current availability.
Research use only. The literature summarised above is preclinical unless otherwise stated.